Early Detection Research Network

Laxman 7-marker panel for prostate cancer

This biomarker is also known as:
  • Laxman 7-marker panel for prostate cancer,


This 7-marker multiplex panel of urine transcripts outperforms PCA3 transcript alone for the detection of prostate cancer. The panel consists of PCA3, AMACR, ERG, GP73 (GOLPH2), SPINK1, TFF3, and TMPRSS2:ERG fusion.


There are no datasets associated with this biomarker.

QA State: Curated
HGNC Name:

Panel Details

The following organs have data associated with this biomarker…


Phase: Two
QA State: Curated


This 7-marker panel has been shown to outperform serum PSA or PCA3 assays alone when used on sedimented urine from patients considered for prostate biopsy or prostatectomy.

Performance Comment

The area under the receiver-operating characteristic curve was 0.758 for the multiplexed model versus 0.662 for PCA3 alone (P = 0.003). The sensitivity and specificity for the multiplexed model were 65.9% and 76.0%, respectively, and the positive and negative predictive values were 79.8% and 60.8%, respectively.

This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at heather.kincaid@jpl.nasa.gov if you should have access to this biomarker.

No associated publications found.

No other associated resources found.